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A hemolytic anti-LKE associated with a rare LKE-negative,
“weak P” red blood cell phenotype: alloanti-LKE and alloanti-P
recognize galactosylgloboside and monosialogalactosylgloboside
(LKE) antigens
Laura Cooling,1 Louann R. Dake,1 Donna Haverty,3 Nancy Mullis,3 Susie Ellis,4 James Shayman,2
and W. John Judd1
BACKGROUND: “Weak P” is a rare red blood cell
(RBC) phenotype, characterized by a global decrease
in Pk and P antigens. We now describe a second weak
P individual who also typed LKE-negative (LKE-N) and
possessed a clinically significant anti-LKE.
STUDY DESIGN AND METHODS: Patient RBCs and
plasma were examined by standard serology and flow
cytometry. Glycosphingolipids (GSLs) from patient, Pk,
and LKE-strong (LKE-S) RBCs were isolated and ana-
lyzed by high-performance thin-layer chromatography
(HPTLC). To confirm antibody specificity, patient serum
and 30 human polyclonal controls, including alloanti-P
and anti-PP1Pk, were tested against a panel of GSLs by
HPTLC immunostaining.
RESULTS: The patient typed P1+, P+, and LKE-N and
possessed a “P-like” panagglutinin. In a two-stage indi-
rect antiglobulin test, the patient’s plasma caused
hemolysis of LKE-S cells but not p, Pk, or LKE-N cells.
Clinically, transfusion of P+ RBCs compatible by a
prewarmed technique had shortened RBC survival with
laboratory evidence of hemolysis. Analysis of the
patient’s isolated RBC GSLs showed a 30% relative
decrease in Gb3 (Pk) and Gb4 (P) and a 90% decrease
in monosialogalactosylgloboside (MSGG, LKE), accom-
panied by increased lactosylceramide (CDH),
paragloboside, and GM3. On HPTLC immunostaining,
the patient’s plasma strongly bound MSSG with weak
binding to galactosylgloboside (Gb5). Binding to MSGG,
Gb5, and Gb4 was also observed with some examples
of alloanti-P from Pk individuals, but not anti-PP1Pk,
autoanti-P, or normal controls.
CONCLUSIONS: We describe the first example of a
clinically significant anti-LKE in the setting of a rare
weak P background. Human alloanti-LKE and some
alloanti-P recognized Gb5 and MSGG.
L
KEis a sialylated, globo-family glycosphingolipid
(GSL)1,2 that is biosynthetically related to the Pk
(Gb3) and P (Gb4) antigens. Like Pk and P anti-
gens, LKE is a high-frequency antigen on human
red blood cells (RBCs), with 98% to 99% of donors typing
LKE-positive.2-7 LKE varies in strength between individu-
als, with 80% to 90% typing LKE-strong (LKE-S) and 10%
to 20% individuals as LKE-weak (LKE-W). LKE-negative
(LKE-N) is reported in 1% to 2% of P+ donors, as well as
rare p and Pk individuals who are deficient in complex
globo-GSLs. Interestingly, there is an apparent inverse
relationship between LKE and Pk, with many LKE-N
donors showing elevated Pk expression reminiscent of a
“Pk variant” phenotype.4,7,8 LKEmay also have interactions
with other carbohydrate blood groups. In uroepithelial
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tissues, LKE can be weakened in the presence of secretor.9
Serologic studies with rare human anti-LKE also suggest
an association between LKE-W, A1, and P2 phenotypes.5,6
Although 1% to 2% of the population types as LKE-N,
alloantibodies to LKE are actually quite rare, with only five
cases mentioned in the literature.5-7,10 All acted as direct
panagglutinins, with most capable of fixing complement
in vitro (Table 1). The first example was found in an
untransfused man with Hodgkin’s disease.5 Two examples
were identified in prenatal samples6,7 and an additional
two were identified in routine testing.10 Based on available
literature, anti-LKE appears to be clinically insignificant.
We now report a sixth example of an alloanti-LKE.
Unlike prior cases, this patient had clinical evidence of
shortened RBC survival and hemolysis after repeated
transfusions with LKE+ blood that was compatible in
prewarmed testing. In addition, we show evidence that
the LKE-N phenotype arose from a “weak P” RBC pheno-
type,11 with weakened expression of all globo-GSLs.
This is the second case of a weak P and the first associated
with a LKE-N phenotype. Finally, we provide the first
direct evidence of human alloanti-LKE binding to
monosialogalactosylgloboside (MSGG), the putative LKE
antigen.
CASE REPORT
The patient was a 58-year-old white man with a history of
gastroesophageal reflux disease, hypertension, Type II
diabetes, atrial fibrillation, congestive heart failure with
an ejection fraction of 25% to 30%, chronic microcytic
anemia, and a 1-year history of a nonpainful right groin
mass. He was initially seen in a local primary care facility,
where he was transfused with 2 RBC units for a hemoglo-
bin (Hb) of 9.7 g/dL. He was referred to a local hospital
1 week later for further evaluation of his anemia. At that
time, his Hb was 7.0 g/dL with a weakly positive direct
antiglobulin test (DAT; 1+, anti-C3 only). In addition, a
cold agglutinin with “P-like” specificity was identified in
his plasma. He received no additional transfusions due to
difficulty finding compatible blood. He was subsequently
transferred to a large regional hospital for management of
his anemia and investigation of his left groin mass.
Upon admission to Hospital 2, the patient was afe-
brile, tachycardic (pulse 104) with a 5 × 3-cm firm,
nontender, left groin mass. A complete blood count was
significant for a hypochromic, microcytic anemia (Hb
7.1 g/dL, MCV 79, MCH 25.9), mild leukocytosis
(17.6 × 109/L), and thrombocytosis (614 × 1011/L). Chem-
istry studies showed a normal serum iron, normal biliru-
bin, mildly depressed transferrin, and elevated ferritin
(11,600 ng/mL; normal range, 12-300 ng/mL) and
haptoglobin (375 mg/dL; normal range, 23-200 mg/dL).
There was no evidence of gastrointestinal bleeding
by endoscopy and stool guaiac tests. A CT scan revealed
splenomegaly with periaortic, iliac, and inguinal
lymphadenopathy: There was no evidence of retroperito-
neal or intrabdominal hemorrhage.
On Hospital Day 2, the patient became hypotensive
and was transfused with 2 units of group O RBCs. Both
units were strongly incompatible (3+) by immediate-spin
(IS) cross-match and weakly (±) reactive in polyethylene
glycol (PEG) indirect antiglobulin tests (IATs), but were
compatible using a prewarmed technique.12,13 Both units
were transfused without incident but failed to elicit the
expected increase inHb, with a posttransfusionHb of only
7.7 g/dL (Fig. 1).
On Day 5, the patient received an additional 2 RBC
units before a scheduled lymph node biopsy. As before,
units were cross-matched by a prewarmed technique. The
patient was medicated before transfusion with acet-
aminophen, diphenhydramine, and dexamethasone. The
patient tolerated transfusion with an appropriate 2 g/dL
increase in Hb; however, his Hb quickly decreased to
pretransfusion levels within 24 hours. Over the next 6
days, the patient was transfused an additional 5 units with
no sustained increase in Hb (Fig. 1A). Transfusions were
accompanied by increased lactate dehydrogenase (LDH),
total bilirubin, and decreasing haptoglobin (Fig. 1B). By
Day 11, the patient was noted to be jaundiced with a total
TABLE 1. Examples of anti-LKE reported in the literature
Case
Age
(years)/sex Ethnicity Diagnosis
Prior
sensitization
Antibody titer
IAT* Significant Reference
Unmodified
RBCs
Enzyme
RBCs
1 32/male Black Hodgkin’s lymphoma No 256 512 C3 NR Tippett, 19655
2 NA/female NA Prenatal Yes, G2P1† 2 4 C3 only No Bruce, 19887
3 32/female Danish Prenatal Yes, G2P1‡ 4 16, IAT IgG‡ No Moller, 19886
4 NA/male Algerian Cardiac No NR NR NR NR Race, 196510
5 NA/female Turkish NR NR “Weak” NR NR NR Race, 196510
6 58/male White Large B-cell lymphoma Unknown§ ND 256 C3 Yes This study
* Reactivity in the IAT (anti-C3, anti-IgG).
† Weak panagglutinin recognized at 4 months during first pregnancy. Antibody specificity not identified until her second pregnancy.
‡ Antibody reportedly sensitive to dithiothreitol, suggesting an IgM antibody. Patient also possessed an anti-P1 reactive at 37°C and anti-IgG.
§ Patient received a 2-unit RBC transfusion 1 week before the discovery of a panagglutinin. The pretransfusion results are not available.
ND = not done; NR = not reported.
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bilirubin of 17.9 mg/dL (64% direct bilirubin), elevated
reticulocytes (4.9%), and low haptoglobin. In addition, his
DAT was 2+ (anti-C3) with spherocytes and rouleaux
noted on a peripheral blood smear.
Given laboratory evidence of a delayed hemolytic
transfusion reaction, it was decided to forego any further
transfusions unless the patient became symptomatic. A
histologic examination of his left inguinal lymph node
revealed a large B-cell lymphoma. On Day 15, the patient
was treated with one course of rituximab, cyclophospha-
mide, and vincristine. He was discharged on Day 17 to the
care of a local oncologist. The patient died 3 months after
discharge of unknown causes.
MATERIALS AND METHODS
Immunologic reagents
Monoclonal antibodies (MoAbs) against P/Gb4
(MoAb MC631),14 LKE/MSGG (MoAb MC18-70),1 and
lactosamine (MoAb FeA5)15 were obtained from theDevel-
opmental Studies Hybridoma Bank held at the University
of Iowa (Iowa City, IA). Shiga toxin (Stx) and anti-Stx IgG
were purchased from Toxin Technology (Sarasota, FL). Stx
was labeled with fluorescein isothiocyanate (FITC) as
described.4 The resulting Stx-free dialysate was retained as
a negative control. SC802, a recombinant P-fimbriated
Escherichia coli strain, and HB101, a nonfimbriated E. coli
control, were a gift from S. Clegg (Department of Microbi-
ology, University of Iowa).16 Biotinylated anti-mouse
(IgG, IgM) and anti-human (IgG, IgM) antibodies,
streptavidin-alkaline phosphatase, and alkaline phospha-
tase substrate were purchased from Vector Laboratories
(Burlingame, CA). FITC-labeled anti-mouse antibodies
(IgG, IgM) and Clostridium perfringens Type IV neur-
aminidase were purchased from Sigma (St Louis, MO).
The immunologic reactivity and structure of various GSL
antigens is shown in Table 2.
Rare human RBCs and antibodies were obtained via
the SCARF International Exchange Program17 and theUni-
versity of Michigan Immunohematology Reference Labo-
ratory. P1k cells for GSL extraction were a gift from R.
Thompson (University of Minnesota). Anti-mouse IgG gel
cards were a gift from H. Malyska (Micro Typing Systems,
Pompano Beach, FL). All other serologic reagents were
from Ortho Clinical Diagnostics (Raritan, NJ) or
ImmucorGamma (Norcross, GA) and used according the
manufacturers’ instructions.
RBC studies
LKE typing was performed with MoAb MC813-70 as
described.4,18 Samples agglutinating at IS were typed as
LKE-S. Negative samples were tested by the IAT using anti-
mouse IgG. Samples negative at IS, but positive by the IAT,
were typed as LKE-W. Samples failing to agglutinate by IS
and IAT were typed as LKE-N. LKE-N samples were tested
for P antigen with MoAb MC631.4,14
Other serologic tests were performed as described
previously.12,13 Reactions were graded and scored
Fig. 1. Patient clinical course following transfusion of P+ RBC
units compatible by a prewarmed cross-match technique over
the course of hospitalization at Hospital 2. (A) Patient’s Hb,
(B) LDH, and (C) haptoglobin (−) and total bilirubin (- -).
Arrows indicate transfusion of group O+, leukoreduced irradi-
ated RBC units.
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according to the method described by Marsh.19 Bacterial
hemagglutination assays using P-fimbriated E. coli were
performed on buffered gel cards (Ortho) as previously
described.20
Flow cytometry
Washed, ficin-treated RBCs were stained with MoAbs or
FITC-labeled Stx and analyzed by one-color flow
cytometry (FACScan, Becton Dickinson, Hialeah, FL) as
described.4 All samples were stained in duplicate and
recorded as the mean percent positive cells and mean
channel fluorescence intensity (MFI).4
High-performance thin-layer chromatography
RBC GSLs were isolated by a modified Leeden and Yu
method as previously described.4,18,21 High-performance
thin-layer chromatography (HPTLC) was performed using
either glass or aluminum-backed HPTLC plates (E. Merck,
Darmstadt, Germany).22,23 For neutral GSL analysis,
HPTLC plates were developed in standard neutral solvent
(C-M-W 65:25:4, vol/vol). Gangliosides were developed in
C-M-0.02% aqueous CaCl2. GSLs were visualized by
chemical staining (diphenylamine, charring) or HPTLC
immunostaining.22,23 GSLs were characterized by relative
mobility (Rf) and relative intensity by scanning densitom-
etry (Quantiscan, Biosoft, Ferguson, MO). GSL standards
were purchased from Sigma or Matreya (Pleasant Gap,
PA). Paragloboside (nLc4), Gb5, MSGG, neutrophil, and
ACHN GSLs were isolated previously.23
HPTLC immunostaining
For immunostaining, HPTLC plates were coated in 0.2%
poly(iso)butyl-methacrylate in hexane for 1 minute and
dried for at least 1 hour at room temperature (RT).18,23 For
stainingwith human antisera, plates were initially blocked
for 1.5 hours with phosphate-buffered saline (PBS)-3%
bovine serum albumin (BSA) and then overlaid with anti-
sera diluted 1:20 in PBS-5%BSA for 2 hours. After washing,
bound antibody was detected by sequential incubation
with biotinylated anti-human immunoglobulin (IgM,
IgG), streptavidin-linked alkaline phosphatase, and black
alkaline phosphatase substrate.18 To estimate relative anti-
body binding, the amount of bound antibody was divided
by total GSL as determined by scanning densitometry
(antibody staining [area]/GSL quantity [area by charring]).
Immunostaining with murine MoAbs and Stx were per-
formed as previously described.4,23,24
Statistical analysis
Quantitative data were expressed as the mean and stan-
dard deviation (SD). Differences in relative GSL expression
were compared by t test. Graphics and statistical analysis
TABLE 2. GSL structures
Name/family Specificity Structure Reagent*
CMH Glucosylceramide Glcβ1-1Cer
CDH Lactosylceramide Galβ1-4Glcβ1-1Cer
GM3 Gd† NeuAcα2-3Galβ1-4Glcβ1-1Cer
Globo-series
Gb3 Pk, CD77 Galα1-4Galβ1-4Glcβ1-1Cer Stx
Gb4 P GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer MC631
Gb5 SSEA-3 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer MC631
Forssman GalNAcα1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer
Globo-H Type 4 H Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer MBr1
MSGG LKE, SSEA-4 NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer MC813-70
DSGG NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ1-1Cer nm/MC631
NeuAcα2-6/ 5F3
Neolacto-series
nLc4 Paragloboside Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer FeA5
αGal-nLc4 P1 antigen Galα1-4Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer Stx
βGalNAc-nLc4 PX2, P-like GalNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer
snLc4 Sialylparagloboside NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer nm/FeA5‡
snLc6 NeuAcα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ1-1Cer nm/FeA5‡
Ganglio-series
GM1 Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1Cer Cholera toxin
GD1a NeuAcα2-3Galβ1-3GalNAcβ1-4(NeuAcα2-3)Galβ1-4Glcβ1-1Cer
GD1b Galβ1-3GalNAcβ1-4(NeuAcα2-8NeuAcα2-3)Galβ1-4Glcβ1-1Cer
* MoAbs and lectins against GSL antigens.
† GM3 is recognized by Gd (glycolipid-dependent) cold agglutinins.
‡ Nm/FeA5, reactive after in situ digestion of gangliosides with neuraminidase, followed by staining with MoAb FeA5.
Cer = ceramide; Fuc = fucose; Gal = galactose; GalNAc = N-acetylgalactosamine; Glc = glucose; GlcNAc = N-acetylglucosamine; Gd = glyco-
lipid-dependent cold agglutinin; NeuAc = N-acetylneuraminic acid; nm = in situ neuraminidase digestion; SSEA = stage-specific embryonic
antigen.
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were performed with commercial software (Kaleidograph,
Synergy Software, Reading, PA).
RESULTS
Serology
RBC typing
The patient’s RBCs typed as groupO,D+, I+, Le(a−b+), P1+.
RBCs were reactive with several anti-globo reagents by
direct agglutination, including anti-PP1Pk, alloanti-P,
MoAb MC631, and P-fimbriated E. coli (Table 3). The
patient typed LKE-N with MoAbMC813-70: No agglutina-
tion was observed with ficin-treated patient RBCs after
4°C incubation or in the IAT with anti-mouse IgG (tube
and gel method).2,4,18
The patient’s DAT was weakly reactive (1+) due to
complement after transfusion of 2 RBC units at a local
facility. ADATdrawn after his last transfusionwas 2+ (anti-
C3, 11 RBCs total). An acid eluate of both samples was
negative by tube method at IS and after incubation at RT
(15 min) and 4°C (30 min, Table 3).
Serum findings
The patient’s plasma contained a weak RT panagglutinin
reactive with 14 of 16 P+ RBCs: No agglutination was
observed against p (n = 4), P1k, P2k, LKE-N (n = 2), and
autologous RBCs (Table 3). Reactivity could be enhanced
by 15-minute RT incubation, 30-minute incubation at 4°C
(4+), and use of ficin-treated RBCs. The direct agglutina-
tion titer against LKE-S RBC was 256 at 4°C.
The plasma was nonreactive at 37°C with low-ionic-
strength saline (30- or 60-min incubation) and in the IAT
by tube and gel method with anti-IgG. The serum was
weakly reactive in PEG-IAT cross-matches with some
random-donor RBCs, but nonreactive with the same cells
by a prewarmed technique.12,13 The serum caused hemo-
lysis of ficin-treated, LKE-S cells in a two-stage IAT by tube
method, using fresh normal serum as a source of comple-
ment and polyspecific anti-human globulin (Table 3).13
Flow cytometry
Patient cells were initially screened for Pk, P, and LKE
expression by flow cytometry.4 RBCs from LKE-S (n = 3),
LKE-N, P1k, and p individuals were included as controls.
Consistent with serologic typing, little or no detectable
LKE was identified on patient RBCs with MoAbMC813-70
(Fig. 2). Unlike the LKE-N and P1k controls, the patient had
no evidence of increased Pk expression.4,7 There was no
significant difference in Pk and P expression between the
patient and the LKE-S controls.
Neutral RBC GSLs
To confirm the results of flow cytometry, GSLs from the
patient’s cells were isolated and analyzed by HPTLC. GSLs
from human granulocytes and P1k and LKE-S RBCs were
included as controls. Neutrophils, like p RBCs, are devoid
of globo-GSLs and express predominantly neolacto-
family GSLs (Table 4).23,25
TABLE 3. RBC and serum reactivity by LKE phenotype*
Cell
RBC typing*† Serum testing‡
ABO Anti-P1 Anti-PP1Pk
Anti-P E. coli§
LKE††
Direct Agglutination|| Two-stage IAT¶
MC631 P-titer** SC802 HB101 IS 15 min, RT 60 min, 37°C AHG Comments
p O 0 0 0 0 0 0 N 0 0 − −
P1K O + 3+ 0 0 0 0 N 0 0 − −
1 O + − 4+ 32 512 0 N 0 0 0 0
2 O + − 3+ 16 256 0 N 0 +/− 0 0
3 O + − − − 1048 0 W − 1+w 0 0
4 O + − − 32 256 0 W − 1+w 0 0
5 O + 3+ 4+ 32 512 0 S 2+ 2+ 0 1+w Hemolysis
6 O + − 4+ 64 1048 0 S 2+ 3+ 0 1+m Hemolysis
7 O + − − − − − S +/− 1+s 0 2+s
8 O + − − − − − S − − 0 2+ Hemolysis
Pt. O 3+ 3+ 2+ 8 512 0 N 0 0 0 1+w 2+ DAT‡‡
* A total of 32 RBC samples were tested against patient serum/plasma. Shown are the reactivity of cells used in the two-stage IAT and flow
cytometry (Fig. 2).
† RBC typing with commercial ABO, anti-P1, human anti-PP1Pk, MoAb MC631, human alloanti-P, and MoAb MC813-70.
‡ Performed with the “posttransfusion” sample obtained by Hospital 2. Patient had been transfused with 11 units of RBCs to date.
§ Gel titer with E. coli SC802 (P-fimbriated) and HB101, a nonfimbriated control against unmodified RBC in buffer-only gel cards.16,20
|| Direct agglutination (tube) at IS, 15-minute RT incubation, and 60-minute incubation at 37°C.
¶ Two-stage IAT performed with ficin-treated RBC, polyspecific AHG, and fresh plasma (serum) as a source of complement.13 Cells were
chosen based on their LKE-phenotype as noted.
** P-titer using human polyclonal alloanti-P with strict Gb4 specificity by HPTLC immunostaining. Testing performed with unmodified RBC
(buffer gel, 1 hour, 4°C). Titer reported as the inverse dilution giving 1+ agglutination.
†† LKE phenotype as determined with MoAb MC81-70.2,4
‡‡ Patient had 2+ DAT after transfusion with 11 units of RBCs.
− = not done; 0 = no agglutination; + = positive. Hemagglutination scoring per routine.13
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Normal RBCs express four major neutral GSLs
(Fig. 3A): glucosylceramide (CMH, Rf = 0.59), lactosyl-
ceramide (CDH, Rf = 0.40), globotriaosylceramide (Gb3,
Rf = 0.25), and globoside (Gb4, Rf = 0.16). Patient RBCs
(Fig. 3A, Lane 7) displayed a 40% decrease in Gb3 and a
25% decrease in Gb4, for an overall 30% decrease in globo-
GSLs relative to LKE-S controls (Table 4). Decreased
globo-GSLs were accompanied by a threefold increase in
CDH and increased expression of a paragloboside-like
GSL (nLc4, Rf = 0.13). An increase in CDH and nLc4 were
also observed in a P1k control.
Neutral GSLs were subsequently immunostained
with reagents against Gb3 (Stx, Fig. 3B),4 Gb4 (MoAb
MC631, Fig. 3C),14 and nLc4 (MoAb FeA5, Fig. 3D;
Table 2)15 to verify the results of chemical staining. The
patient had weak Stx staining to Gb3 and P1 (Fig. 3D, Lane
7). Likewise,MC631 staining toGb4was reduced 50% rela-
tive to LKE-S RBCs. Strong FeA5 staining to nLc4 was
observed in patient, P1k, and a neutrophil control.
As an indirect measure of relative glycosyltransferase
activity, the ratio of product to substrate was determined
by scanning densitometry (Table 4).28,29 Unlike LKE-N
RBCs,4 patient cells had a relatively normal Gb4/Gb3 ratio.
In contrast, there was a fivefold decrease in the Gb3/CDH
ratio, consistent with decreased conversion of CDH→Gb3.
A decrease in Gb3/CDH ratio, accompanied by increases
in CDH and nLc4, is also reported for the weak P pheno-
type.11 As shown, relative neutral GSL expression in our
patient and a knownweak P sample was virtually identical
(Table 4).
RBC gangliosides
HPTLC analysis of the total RBC ganglioside fraction
showed subtle but significant differences in ganglioside
expression between patient (Fig. 3E, Lane 3), P1k (Fig. 3E,
Lane 2), and LKE-S RBCs (Fig. 3E, Lanes 4-6). All RBCs
expressed ganglioside GM3 (Rf = 0.48) and sialopara-
globoside (snLc4, Rf = 0.38), which together comprised
60% to 70% of the total RBC ganglioside by scanning den-
sitometry (Figs. 3H-3J). In LKE-S cells, the ratio of snLc4:
GM3 was approximately 2:1, with snLc4 representing
nearly 50% of the total RBC ganglioside. In patient and P1k
RBCs, the snLc4:GM3 ratio was reduced (1:1) due to a 20%
relative increase in GM3 expression (Figs. 3H and 3I). All
RBC samples, including the patient’s, had evidence of
snLc6 and long-chain, high-molecular-weight (HMW)
Type 2 sialylated gangliosides30-32 upon immunostaining
with MoAb FeA5 (Fig. 3F).15,24
Fig. 2. Globo-GSL analysis by flow cytometry. (A) Flow cytometric histograms of patient, LKE-S, LKE-N, P1k, and p ficin-treated
RBCs stained with FITC-Stx (anti-Gb3), MoAb MC631 (anti-Gb4), and MoAb MC813-70 (anti- LKE, Table 2). Patient sample is
posttransfusion of 2 units of group O RBCs. Also included are negative isotype controls for murine IgM (anti-CD15), IgG (anti-
CD31), and Stx (FITC dialysate4). Line demarcates positively stained cells. Percentages indicate the percent positive cells for each
marker. (B) The MFI of RBCs stained with Stx, MoAb MC631, and MoAb MC813-70. Lane 1 = LKE-S; Lane 2 = patient; Lane
3 = LKE-N; Lane 4 = P1k; Lane 5 = p; Lane 6 = negative control.
◀
TABLE 4. Neutral GSL expression by P and LKE type
RBCs ABO No.‡
Percent neutral GSL (normalized, mean ± SD)* Ratio (area)†
CMH CDH Gb3 Gb4 nLc4 Gb3/CDH Gb4/Gb3
LKE-S O, A 8 1.3 ± 0.7 11.3 ± 3.7 23.5 ± 3.0 58.4 ± 3.6 4.4 ± 0.6 2.38 ± 0.80 2.45 ± 0.44
O 4 1.3 ± 0.7 10.3 ± 1.9 24.4 ± 2.5 57.7 ± 3.2 4.4 ± 0.6 2.56 ± 0.45 2.22 ± 0.16
A 4 1.3 ± 0.8 11.1 ± 1.9 21.6 ± 5.6 54.2 ± 4.6 2.3 ± 0.5 2.20 ± 1.08 2.67 ± 0.54
LKE-N§ A,B,O 3 2.3 ± 1.3 11.1 ± 1.9 31.6 ± 5.6 54.2 ± 4.6 4.3 ± 0.7 2.90 ± 0.65 1.75 ± 0.43
Pk variant|| O 1 NR 11.6 63.8 24.6 NR 5.52 0.38
P1k A 1 1.5 ± 0.4 33.9 ± 3.7 52.0 ± 3.2 0 11.5 ± 1.6 1.65 ± 0.02 0
Weak P¶ A 1 NR 22.5 16.7 40.2 20.6 0.73 2.41
Patient O 1 0.7 ± 0.1 30.6 ± 0.3 13.5 ± 1.8 42.7 ± 4.0 12.3 ± 4.6 0.47 ± 0.06 3.15 ± 0.44
p (PP1Pk-)** NR 4 7.2 ± 0.6 67.4 ± 2.9 0 0 13 ± 2.1 0 0
Granulocytes B 1 1.9 ± 0.6 75.8 ± 2.1 0 0 18.2 ± 2.9 0 0
Patient vs. LKE-S†† NS <0.0001 0.009 0.002 0.0005 0.03 0.046
Patient vs. LKE-N†† NS <0.0001 0.006 0.031 0.019 0.003 0.017
* Relative distribution of CMH, CDH, Gb3, Gb4, and nLc4 as determined by scanning densitometry. The percentages were normalized to
equal 100%.
† Substrate/product ratios for Gb3 (Gb3/CDH) and Gb4 (Gb4/Gb3) synthesis, as determined by scanning densitometry.
‡ Number of RBC GSLs tested or published in the literature.
§ Data taken from Cooling and Kelley.4
|| Data taken from Kundu et al.8
¶ Data from Kundu et al.11
** Data taken from Kundu et al.25 Lactotriaosylceramide (Lc3) content of p RBC averaged 12.2 ± 1.4%.26
†† t-test.
NA = not applicable; NR = not reported; NS = not significant (p > 0.05).
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To identify MSGG/LKE antigen,
RBC gangliosides were immunostained
withMoAbMC813-70 (Fig. 3G).1,2 ACHN
cells were included as an MSGG-
positive control.33,34 As shown, a strong
MC813-70 band was identified in the
ACHN control (Rc, Rf = 0.30) and all
three LKE-S RBCs. A faint, but detect-
able MC813-70 band was identified in
the patient sample (Fig. 3G, Lane 3).
Based on MC813-70 staining intensity,
MSGG in patient samples was 10% that
observed in LKE-S RBCs (p = 0.001,
Fig. 3J). As expected, no staining was
observed in P1k cells, which lack Gb4
and longer chain globo-GSLs.
Titration of globo-antigens on
patient RBCs
The weak P phenotype is reported to
showweakened P expression in titration
studies with some examples of anti-
PP1Pk.11 In titration studies, the patient
had a significantly decreased titer with
one alloanti-P (titer, 8) relative to LKE-N
(n = 3; median titer, 16), LKE-W (n = 4;
titer, 16-32), and LKE-S cells (n = 4; titer,
32-128).18 No difference was observed
with a second alloanti-P sample (data
not shown).
We also performed titration
studies with SC802, a recombinant
P-fimbriated E. coli strain (Table 3).16,20
The P-fimbria adhesion recognizes all
globo-GSLs but is reported to preferen-
tially recognize MSGG.35,36 There was
no difference in agglutination titer or
Marsh score (not shown) between
patient and LKE-S RBCs. As expected,
no agglutination was observed with p
RBCs, which are devoid of globo-GSLs,
or with HB101, a nonfimbriated E. coli
control.
Patient’s antibody recognizes
MSGG and Gb5
To confirm that the patient’s anti-LKE
recognized MSGG, we performed
HPTLC-immunostaining with patient
serum against isolated RBC ganglio-
sides from LKE-S, P1k, and the patient
(Fig. 4). GSLs from ACHN cells were
also included as a control.33 Patient
Fig. 3. HPTLC analysis of isolated RBC GSLs. (A-D) Neutral RBC GSLs chemically
stained with (A) diphenylamine reagent, (B) Stx, (C) MoAb MC631, and (D) MoAb
FeA5. Note faint Stx binding due to high Gb4 concentrations.26,27 Lane 1 = CMH;
Lane 2 = CDH; Lane 3 = Gb3 (Pk antigen); Lane 4 = Gb4 (P antigen); N = neutrophils;
Lane 6 = P1k RBCs; Lane 7 = patient; Lanes 8 through 11, group A LKE-S RBCs; Lanes
12 through 16 = group O, LKE-S RBCs. Each RBC lane contains total neutral GSL
from approximately 250 μL of RBC. Neutral GSLs were separated in neutral solvent
C-M-W, 65:25:4 vol/vol. (E-G) RBC gangliosides stained by (E) charring reagent, (F)
neuraminidase/FeA5,24 and (G) MoAb MC813-70. MSGG identified in ACHN control
(Rc, Rf = 0.30) and LKE-S RBCs, with only faint band in patient sample. Lane 1 = GM3
standard; Lane 2 = P1k RBCs; Lane 3 = patient; Lanes 4 through 6 = LKE-S RBC;
Br = human brain; Rc = ACHN renal carcinoma cell (MSGG+, DSGG+); N = neutro-
phils. Gangliosides were separated in C-M-0.2% aqueous CaCl2 50:40:10 vol/vol. Each
RBC lane contains the total ganglioside fraction from approximately 500 μL of RBCs.
(H-J) Scanning densitometry of RBC gangliosides showing (H) percent GM3, (I)
percent snLc4, and (J) relative concentration of MSGG based on MoAb MC813-70
staining.
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serum strongly bound MSGG in ACHN and LKE-S
RBCs: no staining was observed to patient and P1k
RBCs. The patient’s antibody did not recognize GM3,
ganglio-series gangliosides (Br, Table 2), or disialogalac-
tosylgloboside (DSGG, Table 2; ACHN cells37). The
alloanti-LKE present in patient serum included both
anti-human IgM (Fig. 4C) and anti-IgG (Fig. 4D). Very
faint binding to two HMW RBC gangliosides (Rf = 0.08,
0.04), consistent with complex sialyl-Ii gangliosides
(Fig. 3F), was observed with anti-IgG only.
We also tested patient serum against neutral GSLs.
Faint binding was observed to galactosylgloboside (Gb5,
Fig. 4F), the immediate biosynthetic precursor to MSGG.
On scanning densitometry, the patient’s sera preferen-
tially recognizedMSGG over Gb5when normalized for the
amount of GSL present (p = 0.0001; Fig. 5C). Antibody
binding was also observed to a GSL band near Gb4 in
RBCs, but not in ACHN cells or the Gb4 control. Subse-
quent studies confirmed that patient sera contained anti-
bodies recognizing nLc4 (data not shown). Antibody
binding to nLc4 was also observed in one normal control
(Table 5).
Reactivity of other globo antibodies to MSGG
We subsequently screened a series of human polyclonal
globo antibodies including alloanti-PP1Pk, alloanti-P, and
an autoanti-P from a patient with paroxysmal cold hemo-
globinuria (PCH). Results of human polyclonal reagents
were compared to known anti-globo MoAbs and lectins
(Table 5). Relative antibody binding to individual GSLs
was determined by scanning densitometry (Fig. 5C).
To confirm antibody activity and specificity, antisera
was initially tested against neutral GSLs (Fig. 5A). As
expected, sera from p individuals reacted with Gb3, Gb4,
and P1 antigen with a preference for Gb3 (Fig. 5C). Hetero-
geneous activity was observed with alloanti-P from Pk
individuals, with some examples showing nearly pure
anti-P activity and other examples displaying broader
reactivity (Table 5, Fig. 5C). Four examples of alloanti-P
showed activity against Gb5. PCH serum was specific for
Gb4, as was a historical low-titer “anti-LKE” (UM1314,
Table 5).6,18
When tested against gangliosides (Fig. 5B), two
alloanti-P recognized MSGG, with one example showing
Fig. 4. Patient sera binds MSGG and Gb5 by HPTLC immunostaining. (A-D, G) Gangliosides stained with (A) charring reagent, (B)
MoAb MC813-70, (C) patient serum and anti-human IgM, (D) patient serum and anti-IgG, and (G) control serum, anti-IgM. Patient
serum recognized MSGG in ACHN and LKE-S RBCs. Patient serum did not recognize DSGG present in ACHN cells. Very faint IgG
binding to HMW Ii-active gangliosides (Rf = 0.08, 0.04) was also observed. Lane 1 = GM3 standard; Lane 2 = P1k RBCs; Lane
3 = patient RBCs; Lanes 4 and 5 = group A LKE-S RBCs; Br = human brain; Rc = ACHN. Solvent C-M-0.2% aqueous CaCl2 50:40:10
vol/vol. (E, F, and H) Neutral GSLs stained with (E) charring reagent, (F) patient serum, or (H) normal control. Lane 1 = Gb3; Lane
2 = Gb4 standard; Lane 3 = nLc4 standard; Lane 4 = Gb5 standard; Rc = ACHN; Lanes 5 and 6 = RBC neutrals. Secondary antibody
(F, H) was anti-human IgM. Solvent C-M-W 65:25:4 vol/vol.
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Fig. 5. Relative binding and epitope mapping of globo antibodies. (A) Neutral GSLs stained by charring or with human anti-PP1Pk,
auto-P (PCH), and alloanti-P serum. Antibody staining detected with human anti-IgM. Lane 1 = CDH; Lane 2 = Gb3; Lane 3 = Gb4;
Lane 4 = Gb5; Lane 5 = RBCs; Lane 6 = ACHN. Solvent C-M-W 65:25:4 vol/vol. (B) Gangliosides stained by charring, MoAb MC813-
70, anti-PP1Pk, and alloanti-P. Lane 1 = Brain; Lane 2 = ACHN; Lanes 3 and 4 = LKE-S RBCs. Solvent C-M-0.2% aqueous CaCl2 vol/
vol. (C) Relative antibody binding to Gb3, Gb4, Gb5, and MSGG. Relative binding determined by scanning densitometry (area
[immunostain]/area [charring]). (D) Epitope mapping of anti-globo antibodies. Both patient’s anti-LKE and many alloanti-P recog-
nize the Galβ1→3GalNAc motif present in Gb5 and MSGG. The patient’s anti-LKE was significantly enhanced by the presence of a
terminal α2→3 sialic acid. Relative binding (— = strong; - - - = moderate; · · ·, weak).
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stronger reactivity to MSGG and Gb5 than Gb4 (UM1372;
Figs. 5B and 5C). No binding to MSGG was noted by PCH,
anti-PP1Pk, UM1314, or normal control sera (Table 5). No
sample tested recognized human brain gangliosides.
DISCUSSION
The first example of alloanti-LKE was identified in “Mr.
Luke P.,” a 32-year-old, group B, P+, untransfused, African
American man with diffuse Hodgkin’s lymphoma.5 Sero-
logic studies showed that this “anti-Luke” recognized a
high-incidence RBC antigen that was expressed by P1 and
P2 donors, but not on rare p and Pk RBCs, suggesting that
the Luke antigen was related to the globo-GSL family. This
was strengthened by family and population studies
showing increased Pk expression on LKE-N RBCs.4,7 Over
the next decade, four additional anti-Luke were identified
in P+ individuals.6,7,10 Unlike the original anti-Luke, these
later examples were low-titer panagglutinins (Table 1).
Despite a 1% incidence of LKE-N in the general popula-
tion, anti-LKE remains a rarely encountered antibody. The
latter may reflect the fact that LKE is also expressed on
many nonerythroid tissues.4,39-43
The formal identification of “Luke” as the globo-
ganglioside MSGG occurred in 1988 with the demonstra-
tion that MoAb MC813-70, a MoAb developed against
murine embryonic stem cells, had “Luke-like” activity in
serologic testing.1,2 This was also consistent with the
known RBC serology since MSGG would be absent on p
and Pk RBCs due to the absence of required upstream GSL
precursors necessary forMSGG synthesis (Fig. 6).With the
presumed identification of MSGG as “Luke,” the antigen
was officially renamed LKE for “Luke antigen on erythro-
cytes.”3 Direct evidence of human anti-LKE binding to
MSGG, or any other RBC GSL, has been lacking due to the
scarcity of anti-LKE antisera.
We now present a sixth case of alloanti-LKE. Like the
original Mr. Luke P., the anti-LKE in our patient was a
high-titer, complement-fixing, direct agglutinin capable
of in vitro hemolysis in a two-stage IAT with enzyme-
treated RBCs. Unlike previous anti-LKE described,5-7,10 our
patient’s antibody was also clinically significant with evi-
dence of shortened RBC survival, a positiveDAT, and labo-
ratory evidence of hemolysis in vivo. It is interesting that
the only two known high-titer anti-LKE both occurred in
male patients with newly diagnosed lymphoma, raising
the possibility that anti-LKE arose in response to malig-
nancy. Carbohydrate antibodies are not uncommon in
patients with advanced lymphoma, which commonly
express Gb3, Gb4, and GM1 (Galβ1-3GalNAc, Table 2).44-47
Globo-specific antibodies have been reported in other
globo-rich cancers.48-52
We were also able to demonstrate, for the first time,
direct binding of a human anti-LKE to MSGG, thus con-
firming MSGG as the LKE antigen. In addition to MSGG,
the patient’s antibody showed weak reactivity to Gb5, the
biosynthetic precursor to MSGG. Gb5 is also recognized
by MoAb MC631 and many alloanti-P. Furthermore,
alloanti-P demonstrating strong Gb5 binding also recog-
nized MSGG, suggesting that the Galβ1→3GalNAcβ1-R
may be a common epitope among alloanti-P (Fig. 5D).
Our findings complement an earlier study by Hansson
and colleagues,53 who demonstrated broad reactivity by a
high-titer alloanti-P, which recognized Gb4, Gb5,
Forssman, and a placental ganglioside running near
snLc4. The demonstration of alloanti-P with anti-LKE
TABLE 5. Reactivity of human polyclonal and monoclonal globo antibodies and lectins by HPTLC
Neutral GSLs Gangliosides
CDH Gb3 Gb4 Gb5 P1 nLc4 GM3 snLc4 MSGG DSGG Sialyl-Ii
Human
Anti-PP1Pk* 0/5 5/5 5/5 0/5 5/5 0/5 0/2 0/2 0/2 0/2 0/2
Allo-P* 0/8 3/8 8/8 4/8 0/8 0/8 0/4 0/4 2/4 0/4 1/4
PCH 0 0 ++ 0 0 0 0 0 0 0 0
UM13146,18 0 0 + 0 0 0 0 + 0 0 w+
Patient 0 0 0 + 0 + 0 0 +++ 0 w+
Normal* 0/8 0/8 0/8 0/8 0/8 1/8 0/6 0/6 0/6 0/6 0/6
Murine
MC63114 0 0 ++ ++ 0 0 0 0 +/− 0 0
Nm/MC6311† 0 0 ++ ++ 0 0 0 0 +++ ++ 0
MC813-701 0 0 0 0 0 0 0 0 +++ 0 0
B2/B134 0 0 0 0 0 0 0 0 + 0 0
RM134,37,38 0 0 0 0 0 0 0 0 ++ 0 0
5F337 0 0 0 0 0 0 0 0 0 ++ 0
Lectins
Stx 0 +++ +/− 0 + 0 0 0 0 0 0
E. coli SC802 0 + + + + 0 0 0 + + 0
E. coli HB101 0 0 0 0 0 0 0 0 0 0 0
* Results expressed as number positive/total number of samples tested.
† In situ digestion of gangliosides to expose cryptic Gb5 epitopes, followed by immunostaining with MoAb MC631.
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activity suggests that some examples of alloanti-P could
behave as an anti-P/LKE with stronger reactivity against
LKE-S RBCs due to higher expression of both P and LKE
antigens (Table 3).
Most examples of LKE-N described to date share fea-
tures of the Pk variant phenotype, with elevated Gb3/Pk
expression.4,8 Our patient is the first known example of
LKE-N arising from a weak P phenotype and is only the
second example of weak P characterized in the literature.
The first weak P was identified serendipitously in a
normal donor after routine phenotyping showed weaker
agglutination with some anti-PP1Pk.11 Analysis of the
donor’s RBC GSLs showed a 30% decrease in globo-GSL
expression, accompanied by a two- to fourfold increase
in CDH, nLc4, GM3, and total RBC ganglioside. As we
have shown, our patient also displayed significant
decreases in Gb3 and Gb4 with compensatory increases
in CDH, nLc4, and GM3. In fact, a comparison of relative
neutral RBC GSL expression between our patient and the
original weak P are virtually identical (Table 4). Unlike
our patient, the original weak P donor was of Chinese
ancestry and did not possess any atypical RBC antibod-
ies in his plasma.
The etiology of the weak P phenotype is unknown.
Kundu and coworkers11 hypothesized a partial block in
α4GalT1, the α1,4-galactosyltransferase responsible for
Gb3 synthesis. As a result, weak P RBCs have a decrease in
all globo-GSLs with a compensatory increase in CDH,
GM3, and neolacto-GSLs (nLc4, snLc4) similar to that
observed in the Pk and p phenotype (Fig. 6).11,25 The basis
for decreased α4GALT1 activity is unknown although one
obvious possibility is heterozygosity for a null A4GALT1
allele. Family studies in p kindreds, however, have shown
normal RBC GSL expression in heterozygous family
members.11,25 Alternatively, Kundu and colleagues11 pro-
posed inheritance of a mutant A4GALT1 allele with func-
tionally decreased enzyme activity. Unfortunately, we
were unable to sequence the patient’s A4GALT1 gene.
In summary, we report the first case of a clinically
significant anti-LKE, capable of binding MSGG, in a male
patient with lymphoma. This is the second case of weak P
described and is the first associated with an anti-LKE.
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Fig. 6. Schematic of GSL synthesis in patient and weak P individuals. Unlike normal individuals, there is an apparent decrease in
α4GalT1 activity, the first committed enzyme for globo-GSL synthesis. As a result, there is a global decrease in all globo-GSLs
including Pk, P, and LKE and a compensatory increase in neolacto-series GSLs. There is also an increase in CDH and GM3 in these
individuals.
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